Dimensional Fund Advisors LP Increases Position in The Chemours Company (NYSE:CC)

Dimensional Fund Advisors LP raised its stake in The Chemours Company (NYSE:CC - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,779,702 shares of the specialty chemicals company's stock after acquiring an additional 328,414 shares during the period. Dimensional Fund Advisors LP owned approximately 1.19% of Chemours worth $30,077,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CC. GAMMA Investing LLC boosted its stake in Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 765 shares during the period. Quadrant Capital Group LLC raised its position in Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours during the fourth quarter valued at approximately $48,000. KBC Group NV raised its holdings in shares of Chemours by 38.2% in the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after buying an additional 1,708 shares during the period. Finally, Sterling Capital Management LLC lifted its stake in shares of Chemours by 54.8% during the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock worth $143,000 after acquiring an additional 2,991 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Stock Down 1.1%

Chemours stock traded down $0.12 during trading on Friday, reaching $11.12. The stock had a trading volume of 7,192,895 shares, compared to its average volume of 1,962,638. The Chemours Company has a 52-week low of $9.33 and a 52-week high of $29.21. The business has a 50 day moving average price of $12.55 and a 200 day moving average price of $16.51. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The stock has a market cap of $1.66 billion, a PE ratio of 19.51 and a beta of 1.76.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.36 billion. During the same period in the previous year, the business posted $0.32 EPS. The firm's revenue for the quarter was up .4% compared to the same quarter last year. On average, analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 8.99%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's dividend payout ratio is presently 500.00%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Truist Financial reduced their target price on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. StockNews.com cut shares of Chemours from a "hold" rating to a "sell" rating in a research report on Thursday. BMO Capital Markets decreased their price target on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. Morgan Stanley dropped their price objective on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Mizuho set a $15.00 price objective on Chemours in a report on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Chemours presently has an average rating of "Hold" and a consensus target price of $19.11.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.